The short version of HGF/c-Met fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-19. Anything still debated is marked as such rather than presented as settled.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Acad. Sci. USA. Thomas Cech (b. 1947). American biochemist at the University of Colorado, famous for discovering catalytic properties of RNA. Member Natl. Acad. Sci. USA. Nobel prize in chemistry, along with Sidney Altman, in 1989. Howard Cedar (b. 1943). Israeli American biochemist at the Hebrew University of Jerusalem, working on DNA methylation, awarded the Israel Prize in Biology in 1999. Member of the Israel Academy of Sciences and Humanities.
== Clinical use == Metirosine has been shown to suppress catecholamine synthesis and alleviate symptoms related to catecholamine excess, including hypertension, headache, tachycardia, constipation, and tremor.
== Further reading == Aziz, Nusrate; Asadullah, M Niaz (2017). "Military spending, armed conflict and economic growth in developing countries in the post–Cold War era" (PDF). Journal of Economic Studies. 44 (1): 47–68. doi:10.1108/JES-01-2015-0021. Bartel, Fritz (2022). The Triumph of Broken Promises: The End of the Cold War and the Rise of Neoliberalism. Harvard University Press. ISBN 9780674976788. Henriksen, Thomas H. (2017). Cycles in US Foreign Policy Since the Cold War. Palgrave Macmillan. Jones, Bruce D.; Stedman, Stephen John (2017). "Civil Wars & the Post–Cold War International Order". Dædalus. 146 (4): 33–44. Menon, Rajan; Rumer, Eugene B., eds. (2015). Conflict in Ukraine: The Unwinding of the Post–Cold War Order. MIT Press. Peterson, James W. (2017). Russian-American relations in the post–Cold War world. Oxford UP. Sakwa, Richard (2017). Russia against the Rest: The Post–Cold War Crisis of World Order. Cambridge UP. p. 362. Wood, Luke B. (2017). "The politics of identity and security in post–Cold War Western and Central Europe". European Politics and Society. 18 (4): 552–556. doi:10.1080/23745118.2017.1376444.
The main isotopes of argon found on Earth are 40Ar (99.6%), 36Ar (0.34%), and 38Ar (0.06%). Naturally occurring 40K, with a half-life of 1.25×109 years, decays to stable 40Ar (11.2%) by electron capture or positron emission, and also to stable 40Ca (88.8%) by beta decay. These properties and ratios are used to determine the age of rocks by K–Ar dating. In Earth's atmosphere, 39Ar is made by cosmic ray activity, primarily by neutron capture of 40Ar followed by two-neutron emission. In the subsurface environment, it is also produced through neutron capture by 39K, followed by proton emission. 37Ar is created from the neutron capture by 40Ca followed by an alpha particle emission as a result of subsurface nuclear explosions. It has a half-life of 35 days. Between locations in the Solar System, the isotopic composition of argon varies greatly. Where the major source of argon is the decay of 40K in rocks, 40Ar will be the dominant isotope, as it is on Earth. Argon produced directly by stellar nucleosynthesis is dominated by the alpha-process nuclide 36Ar. Correspondingly, solar argon contains 84.6% 36Ar (according to solar wind measurements), and the ratio of the three isotopes 36Ar : 38Ar : 40Ar in the atmospheres of the outer planets is 8400 : 1600 : 1. This contrasts with the low abundance of primordial 36Ar in Earth's atmosphere, which is only 31.5 ppmv (= 9340 ppmv × 0.337%), comparable with that of neon (18.18 ppmv) on Earth and with interplanetary gasses, measured by probes.
Sources: en.wikipedia.org
== Contraindications == Nicotine use for tobacco cessation has few contraindications. It is not known whether nicotine replacement therapy is effective for smoking cessation in adolescents, as of 2014. It is therefore not recommended to adolescents. It is not safe to use nicotine during pregnancy or breastfeeding, although it is safer than smoking. The desirability of NRT use in pregnancy is therefore debated. Randomized trials and observational studies of nicotine replacement therapy in cardiovascular patients show no increase in adverse cardiovascular events compared to those treated with placebo. Using nicotine products during cancer treatment may be contraindicated, as nicotine may promote tumour growth, but temporary use of NRTs to quit smoking may be advised for harm reduction. Nicotine gum is contraindicated in individuals with temporomandibular joint disease. People with chronic nasal disorders and severe reactive airway disease require additional precautions when using nicotine nasal sprays. Nicotine in any form is contraindicated in individuals with a known hypersensitivity to nicotine.
== History == Aga Khan University Hospital was established in 1985 with a US$300 million investment from Prince Karim Aga Khan. The government of Muhammad Zia-ul-Haq provided an 84-acre site in the heart of Karachi for the University Hospital at no cost.
Heroin-assisted treatment (HAT), or diamorphine-assisted treatment, refers to a type of Medication-Assisted Treatment (MAT) where semi-synthetic heroin is prescribed to opioid addicts who do not benefit from, or cannot tolerate, treatment with one of the established drugs used in opioid replacement therapy such as methadone or buprenorphine/naloxone (brand name Suboxone). For this group of patients, heroin-assisted treatment has proven superior in improving their social and health situation. Heroin-assisted treatment is fully a part of the national health system in Switzerland, Germany, the Netherlands, Canada, and Denmark. Additional trials are being carried out in the United Kingdom, Norway, and Belgium.
Sources: en.wikipedia.org
The interpretation has been described as the "official" United States version of Cold War history. Although it lost its dominance as a mode of historical thought in academic discussions in 1960s, it continues to be influential.
Ricin toxin vaccines have emerged as a focus in biodefense research. Two recombinant A subunit (RTA)-based vaccines, RiVax and RVEc (also known as RTA1-33/44-198), have completed Phase I clinical trials, and were found to be safe. These vaccines are based on modified versions of the ricin toxin A-chain, designed to reduce toxicity while maintaining immunogenicity. A biopharmaceutical company called Soligenix, Inc. licensed an anti-ricin vaccine called RiVax from Vitetta et al. at UT Southwestern. The vaccine was found safe and immunogenic in mice, rabbits, and humans. Two successful clinical trials were completed. Soligenix was issued a US patent for Rivax. The ricin vaccine candidate was granted orphan drug status in the US and the EEC and, as of 2019, was in clinical trials in the US. Grants from the National Institute of Allergy and Infectious Diseases and the US Food and Drug Administration supported development of the vaccine candidate.
=== From organic halides and cyanide salts === Two salt metathesis reactions are popular for laboratory scale reactions. In the Kolbe nitrile synthesis, alkyl halides undergo nucleophilic aliphatic substitution with alkali metal cyanides. Aryl nitriles are prepared in the Rosenmund-von Braun synthesis. In general, metal cyanides combine with alkyl halides to give a mixture of the nitrile and the isonitrile, although appropriate choice of counterion and temperature can minimize the latter. An alkyl sulfate obviates the problem entirely, particularly in nonaqueous conditions (the Pelouze synthesis). In the Kolbe nitrile synthesis (a nucleophilic substitution reaction), an alkanonitrile and an alkali halide are formed from a reactive halocarbons and an alkali cyanide (sodium cyanide or potassium cyanide). The reaction is particularly suitable for primary, allylic, and benzylic halides. Secondary alkyl halides provide lower yields, whereas tertiary halides undergo exclusively elimination reaction instead of substitution. In addition to halides, substrates bearing other good leaving groups may also be employed. In contrast to alkali cyanides, silver cyanide is unsuitable for nitrile synthesis, as it preferentially forms isonitriles. An example of the Kolbe nitrile synthesis is the reaction of methyl iodide with sodium cyanide to yield acetonitrile and sodium iodide:
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.